Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538 (Nivolumab) PK Study in Solid Tumors
NCT02261285Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2014
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in solid tumor (3 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Maximum Serum Concentration (Cmax) of ONO-4538 at 3 weeks, Time to Maximum Serum Concentration (Tmax) of ONO-4538 at 3 weeks and 3 more. Started Oct 2014; status: completed.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02261285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02261285.